Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Trajan Group Holdings Ltd ( (AU:TRJ) ) has shared an update.
Trajan Group Holdings Ltd announced a strong financial performance for FY25, with record revenue of $166.5M, surpassing its financial guidance despite a $3.9M loss from a discontinued biotech syringe revenue stream. The company experienced a 7.4% growth compared to FY24, outperforming the global scientific instruments sector. However, the Group nEBITDA fell short of expectations due to factors like unfavorable FX revaluation and delayed shipments. Trajan’s cash position improved, with cash and equivalents rising to $11.9M and net debt reduced to $29.6M, indicating a stronger financial footing. The company is optimistic about continued EBITDA and margin expansion in FY26, supported by its diversified portfolio and strong customer relationships.
The most recent analyst rating on (AU:TRJ) stock is a Buy with a A$1.20 price target. To see the full list of analyst forecasts on Trajan Group Holdings Ltd stock, see the AU:TRJ Stock Forecast page.
More about Trajan Group Holdings Ltd
Trajan Group Holdings Ltd is a global developer and manufacturer of analytical and life sciences products and devices, aimed at enhancing personal health through scientific tools and solutions. The company’s products are utilized in the analysis of biological, food, and environmental samples, supporting a shift towards decentralized, personalized data-based healthcare. Trajan operates with over 600 employees across seven manufacturing sites in the US, Australia, Europe, and Malaysia, with operations spanning Australia, the US, Asia, and Europe.
Average Trading Volume: 39,698
Technical Sentiment Signal: Sell
Current Market Cap: A$115.8M
Find detailed analytics on TRJ stock on TipRanks’ Stock Analysis page.